SG Americas Securities’s Niagen Bioscience NAGE Stock Holding History

SG Americas Securities’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,424	Closed	-$77K	–	3729
2026 Q1	$77K	Sell	17,424 -37,225	-68%	-$201K	﹤0.01%	2981
2025 Q4	$348K	Buy	54,649 +2,950	+6%	+$20.5K	﹤0.01%	2683
2025 Q3	$482K	Buy	+51,699	New	+$522K	﹤0.01%	2149
2025 Q2	–	Sell	-17,261	Closed	-$119K	–	3726
2025 Q1	$119K	Sell	17,261 -6,596	-28%	-$41.4K	﹤0.01%	2915
2024 Q4	$127K	Buy	23,857 +7,117	+43%	+$39K	﹤0.01%	2546
2024 Q3	$61K	Buy	+16,740	New	+$52.7K	﹤0.01%	3206
2024 Q2	–	Sell	-15,423	Closed	-$54K	–	3390
2024 Q1	$54K	Buy	+15,423	New	+$28.5K	﹤0.01%	2751
2021 Q4	–	Sell	-20,487	Closed	-$128K	–	3876
2021 Q3	$128K	Buy	+20,487	New	+$169K	﹤0.01%	3544
2021 Q2	–	Sell	-11,802	Closed	-$110K	–	3300
2021 Q1	$110K	Buy	+11,802	New	+$93.5K	﹤0.01%	3035
2020 Q3	–	Sell	-22,300	Closed	-$102K	–	3559
2020 Q2	$102K	Buy	+22,300	New	+$99.8K	﹤0.01%	3362
2016 Q4	–	Sell	-28,382	Closed	-$85K	–	3521
2016 Q3	$85K	Buy	+28,382	New	+$104K	﹤0.01%	3110

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SG Americas Securities's NAGE Position: Q2 2026 in Review

SG Americas Securities sold out of Niagen Bioscience (NAGE) in Q2 2026, closing a stake of 17,424 shares — an estimated $77K sold.

SG Americas Securities first reported a position in NAGE in Q3 2016 and held it in 11 quarters. The position peaked at $482K in Q3 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

SG Americas Securities reported no remaining Niagen Bioscience position as of Q2 2026 after selling out during the quarter.
SG Americas Securities sold 17,424 Niagen Bioscience shares in Q2 2026, an estimated $77K.
SG Americas Securities first reported a position in Niagen Bioscience in Q3 2016 and held it in 11 quarters.
SG Americas Securities's Niagen Bioscience position peaked at $482K in Q3 2025.
140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.